If you are not a current client of Bereskin & Parr LLP, please do not include any information in this email that you or someone else considers confidential. You do not become a client of the firm until the firm agrees to act for you and confirms representation in writing. Until that time what you send us cannot be protected from disclosure.
Ainslie is a lawyer and registered patent agent in Canada and the United States. Ainslie’s practice focuses on life sciences matters, including patents, licensing, and related litigation. She works closely with clients in preparing and prosecuting patent applications relating to pharmaceuticals, biologics, diagnostics, biotechnology and plant technologies. Ainslie also has experience in the analysis of patent issues such as validity, infringement and freedom to operate. Ainslie has worked on matters involving Food and Drugs Act compliance.
While obtaining her Ph.D. from the University of Toronto, Ainslie conducted research directed to identifying the mode-of-action of small molecules using genomic technologies.
Ainslie has authored a number of professional papers including, "Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast" published in Cell and "The integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways," published in Nature Biotechnology.
Ainslie is the recipient of the CIHR (Canadian Institutes of Health Research) Canada Graduate Scholarship Doctoral Award and the NSERC (Natural Sciences and Engineering Research Council of Canada) Post-Graduate Scholarship.
Ainslie is currently a member of the Rethink Breast Cancer R3 National Advisory Committee.
Canadian Bar Association (CBA) Intellectual Property Institute of Canada (IPIC), Affiliate